| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to oncogynaecology, and can be used in treating initial endometrial cancer. The method involves administration of the release gonadotrophin agonist Lucrine-depot (RGn-A) combined with the intrauterine levonorgestrel release system Mirena (LNG-RS). In atypical endometrial hyperplasia (AEH), the RGn-A Lucrine-depot is introduced 3.75 mg 3 times every 28 days; a positive course of the disease requires the administration of the LNG-RS with underlying continuing therapy by the RGn-A 3.75 mg 3 times every 28 days, for the purpose of prevention of the recurrent disease, the LNG-RS is used for at least 6 months. In endometrial cancer (EC), the RGn-A 3.75 mg is introduced. once in 28 days in 3 injections; the positive course of the disease implies the administration of the RGn-A 3.75 mg once in 28 days in 5 injections; the third injection is followed by the administration of the LNG-RS for at least 1 year. ^ EFFECT: use of the invention allows providing higher clinical effectiveness in initial endometrial cancer in women of childbearing age, reducing length of treatment and rehabilitation in the patients, eliminating hormonotherapy associating complications - postinjection abscesses and thrombophlebitises. ^ 2 ex |
